A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis.

JHEP Rep · 2023 · PMC9832280 · PMID 36644237

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Circulating biomarkers of liver function (albumin, bilirubin, MELD, C–P scores) appeared unchanged, while most markers of hemostasis were either preserved (platelets, clotting time) or showed a trend towards improvement (PAI-1).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.